Condition
MAP Kinase Family Gene Mutation
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Terminated2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06104488Phase 1Recruiting
A Study of Avutometinib for People With Solid Tumor Cancers
NCT04985604Phase 2Terminated
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
NCT07121829Phase 1Terminated
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Showing all 3 trials